Trending NewsTrending NewsNASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $59.01 +2.59 (+4.59%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$58.50 -0.51 (-0.86%) As of 06/18/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeneDx Stock (NASDAQ:WGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeneDx alerts:Sign Up Key Stats Today's Range$57.00▼$59.4350-Day Range$34.51▼$69.8352-Week Range$32.21▼$170.87Volume658,675 shsAverage Volume1.18 million shsMarket Capitalization$1.75 billionP/E RatioN/ADividend YieldN/APrice Target$96.43Consensus RatingModerate Buy Company Overview GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting. Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards. GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.AI Generated. May Contain Errors. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 92% of companies evaluated by MarketBeat, and ranked 45th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGeneDx has a consensus price target of $96.43, representing about 63.4% upside from its current price of $59.01.Amount of Analyst CoverageGeneDx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GeneDx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($1.00) to $0.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -22.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -22.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted21.87% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 3.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeneDx has recently decreased by 7.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.14 News SentimentGeneDx has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for GeneDx this week, compared to 8 articles on an average week.Search InterestOnly 13 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat Follows6 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of GeneDx in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $88,883,936.00 in company stock, which represents 5.0733% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have bought 2,086.28% more of their company's stock than they have sold. Specifically, they have bought $93,144,340.00 in company stock and sold $4,260,404.00 in company stock.Percentage Held by Insiders25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WGS Stock News HeadlinesGeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 3,729 Shares of Stock 1 minute ago | insidertrades.comGeneDx Appoints Mark Gardner as New Company PresidentJune 18 at 11:39 PM | theglobeandmail.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.June 19 at 1:00 AM | Porter & Company (Ad)GeneDx Holdings Corp. (WGS) Class Action Lawsuit Seeks Recovery for Investors; August 3, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLPJune 18 at 5:30 PM | globenewswire.comHagens Berman Alerts GeneDx Holdings (WGS) Investors to Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics AcquisitionJune 18 at 1:14 PM | globenewswire.comKevin Feeley Sells 1,266 Shares of GeneDx (NASDAQ:WGS) StockJune 12, 2026 | insidertrades.comCasdin Capital, Llc Purchases 50,000 Shares of GeneDx (NASDAQ:WGS) StockJune 9, 2026 | insidertrades.comFrom Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading (WGS)Check out these three stocks that insiders are buying and selling, including giants in oil and AI, as well as a small gene stock seeing huge swings.June 6, 2026 | marketbeat.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $130.06 at the beginning of the year. Since then, WGS shares have decreased by 54.6% and is now trading at $59.01. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) posted its quarterly earnings data on Monday, May, 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.22. The firm earned $102.25 million during the quarter, compared to analyst estimates of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive trailing twelve-month return on equity of 9.15%. Read the conference call transcript. When did GeneDx's stock split? GeneDx shares reverse split on the morning of Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? Top institutional investors of GeneDx include Amova Asset Management Americas Inc. (2.18%), Sumitomo Mitsui Trust Group Inc. (2.16%), Bank of New York Mellon Corp (1.08%) and Dimensional Fund Advisors LP (0.91%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Katherine Stueland, Kevin Feeley, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Joshua Ruch, Jason Ryan, Karen Ann White and Bryan Dechairo. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings5/04/2026Today6/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 As of 4 days ago, WGS's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,300Year Founded2000Price Target and Rating Average Price Target for GeneDx$96.43 High Price Target$150.00 Low Price Target$70.00 Potential Upside/Downside+63.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.02 million Net Margins-17.58% Pretax Margin-17.50% Return on Equity9.15% Return on Assets5.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.09 Quick Ratio2.95 Sales & Book Value Annual Sales$427.54 million Price / Sales4.10 Cash Flow$2.40 per share Price / Cash Flow24.61 Book Value$10.54 per share Price / Book5.60Miscellaneous Outstanding Shares29,690,000Free Float22,216,000Market Cap$1.75 billion OptionableOptionable Beta1.96 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:WGS) was last updated on 6/19/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....InvestPub | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
